Quris, a Boston and Israel-based artificial intelligence (AI) innovator disrupting the pharmaceutical arena, announced the final close of $28 million in a seed funding round led by Welltech Ventures, with participation from iAngels, Glenrock Capital, and others.
The funding will fast-track Quris’ novel drug research and development, team expansion, and partner-building efforts as it scales to rapidly scan 100s of drug candidates to train its AI engine in its mission to revolutionize the drug development process.
Company: Quris Technologies LTD.
Round: Seed Round
Funding Month: January 2022
Lead Investors: Welltech Ventures
Additional Investors: iAngels, and GlenRock Capital
Company Website: https://www.quris.ai/
Software Category: Bio-AI Clinical Prediction Platform
About the Company: Quris is an artificial intelligence innovator that is disrupting the drug development process, aims to disrupt drug development by better predicting which drug candidates will safely work in humans – ensuring the safety and efficacy of new drugs and the repurposing and personalization of existing drugs. Quris's Bio-AI Clinical Prediction Platform better predicts which drug candidates will safely work in humans, avoiding the tremendous costs of failed clinical trials. Using Quris’ patented Chip-on-Chip technology to test thousands of known and novel drug candidates on hundreds of its genetically diverse, miniaturized patients-on-a-chip, its automated, self-training BioAI platform generates proprietary data and uses machine learning to quickly predict clinical safety and efficacy. Dual-headquartered in Boston and Israel and backed by strategic biotech and big data investors, Quris is led by a proven team of AI and medical research powerhouses who are already preparing its lead discovery for clinical testing.